Age effects on placebo response rates in clinical trials of acute agents for migraine: Pooled analysis of rizatriptan trials in adults

Cephalalgia

Volumn 29, Issue 7, 2009, Pages 711-718

  Ho, T W ^a   Fan, X ^a   Rodgers, A ^a   Lines, C R ^a   Winner, P ^b   Shapiro, R E ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Palm Beach Headache Center   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Age; Placebo response; Prior triptan use; Rizatriptan; Sex

Indexed keywords

PLACEBO; RIZATRIPTAN;

ADULT; AGE DISTRIBUTION; AGED; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; GROUPS BY AGE; HUMAN; MIGRAINE; PAIN ASSESSMENT; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES; YOUNG ADULT;

EID: 66749177734     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2008.01788.x     Document Type: Article

References (22)

1. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT-1b/1d agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001 358 : 1668 75.
2. Major PW, Grubisa HS, Thie NM. Triptans for treatment of acute pediatric migraine: a systematic literature review. Pediatr Neurol 2003 29 : 425 9.
3. Silver S, Gano D, Gerretson P. Acute treatment of paediatric migraine: a meta-analysis of efficacy. J Paediatr Child Health 2008 44 : 3 9. (Pubitemid 350233434)
4. Lewis DW, Winner P, Wasiewski W. The placebo responder rate in children and adolescents. Headache 2005 45 : 232 9.
5. Evers S. Oral rizatriptan - an effective migraine therapy in pediatric patients?: Commentary. Nat Clin Pract Neurol 2007 3 : 196 7.
6. Winner P, Lewis D, Visser WH, Jiang K, Ahrens S, Evans JK. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache 2002 42 : 49 55. (Pubitemid 34136611)
7. Visser WH, Winner P, Strohmaier K, Klipfel M, Peng Y, McCarroll K et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache 2004 44 : 891 9.
8. Ferrari MD, Loder E, McCarroll KA, Lines CR. Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia 2001 21 : 129 36.
9. Martin VT, Valade D, Almas M, Hettiarachchi J, Sikes C, Albert KS et al. Efficacy of eletriptan in triptan-naive patients: results of a combined analysis. Headache 2007 47 : 181 8.
10. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988 8 : 1 96.
11. Waber RL, Shiv B, Carmon Z, Ariely D. Commercial features of placebo and therapeutic efficacy. JAMA 2008 299 : 1016 17.
12. Ahonen K, Hamalainen ML, Eerola M, Hoppu K. A randomized trial of rizatriptan in migraine attacks in children. Neurology 2006 67 : 1135 40.
13. Evers S, Rahmann A, Kraemer C, Kurlemann G, Debus O, Husstedt IW, Frese A. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology 2006 67 : 497 9.
14. Lewis DW, Winner P, Hershey AD, Wasiewski WW. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics 2007 120 : 390 6.
15. Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache 1998 38 : 281 7.
16. Kramer MS, Matzura-Wolfe D, Polis A, Getson A, Amaraneni PG, Solbach MP et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology 1998 51 : 773 81.
17. Lines C, Visser WH, Vandormael K, Reines SA, on behalf of the Rizatriptan/Sumatriptan Comparison Study Group. Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine. Headache 1997 37 : 319 20.
18. Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998 38 : 748 55.
19. Dahlof C, Lines C. Rizatriptan: a new 5-HT1B/1D receptor agonist for the treatment of migraine. Expert Opin Investig Drugs 1999 8 : 671 85.
20. Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block GA et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache 1998 38 : 737 47.
21. Ahrens SP, Farmer MV, Williams DL, Willoughby E, Jiang K, Block GA et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia 1999 19 : 525 30.
22. Kolodny A, Polis A, Battisti WP, Johnson-Pratt L, Skobieranda F. Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets. Cephalalgia 2004 24 : 540 6.